Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.

ABSTRACT: Pancreatic ductal adenocarcinoma has limited treatment options. There is an urgent need for developing appropriate pre-clinical models recapitulating metastatic disease, the most common clinical scenario at presentation. Ascites accumulation occurs in up to 20-30% of patients with pancreatic cancer; this milieu represents a highly cellular research resource of metastatic peritoneal spread. In this study, we utilized pancreatic ascites/pleural effusion cancer cells to establish patient derived xenografts.Ascites/pleural effusion-patient derived xenografts were established from twelve independent cases. Xenografts were serially passed in nude mice and tissue bio-specimen banking has been established. Histopathology of emergent tumors demonstrates poorly to moderately differentiated, glandula

SUBMITTER: Golan T 

PROVIDER: S-EPMC5522335 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature